Evidence map›Paper›PMID 38602399›Full record

ArticleMicrobiology spectrum2024

Comparison of targeted next-generation sequencing and the Xpert MTB/RIF assay for detection of

Hongtai Zhang, Xiaowei Dai, Peilei Hu, Lili Tian, Chuanyou Li, Beichuan Ding, Xinyu Yang, Xiaoxin He

Abstract readComparative Study
In one paragraph

Article in Microbiology spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hongtai Zhang *Beijing Center for Disease Prevention and Control, Beijing, China.ORCID 0000-0001-9308-5872
Xiaowei Dai *Beijing Center for Disease Prevention and Control, Beijing, China.
Peilei HuHunan Chest Hospital, Changsha, Hunan Province, China.
Lili TianBeijing Center for Disease Prevention and Control, Beijing, China.
Chuanyou LiBeijing Center for Disease Prevention and Control, Beijing, China.
Beichuan DingBeijing Center for Disease Prevention and Control, Beijing, China.
Xinyu YangBeijing Center for Disease Prevention and Control, Beijing, China.ORCID 0009-0007-3844-9830
Xiaoxin HeBeijing Center for Disease Prevention and Control, Beijing, China.ORCID 0009-0005-3590-0302

Funding

| Natural Science Foundation of Beijing Municipality (Beijing Natural Science Foundation) 7242078Research and Cultivation Special Project of Beijing Center for Disease Prevention and Control BJCDC/2023-KYJH-06the Capital's Funds for the health improvement and Research 2024-2G-3017the Capital's Funds for the Health improvement and Research 2022-1G-3012the Fund of Hunan Provincial Health Commission 202111001302
6 · The paper itself

Abstract

Targeted next-generation sequencing (tNGS) can be used to perform

Indexed as

High-Throughput Nucleotide SequencingMycobacterium tuberculosisRifampinSputumTuberculosis, PulmonaryAdultBacterial ProteinsDNA, BacterialDNA-Directed RNA PolymerasesDrug Resistance, BacterialFemaleHumansMaleMicrobial Sensitivity TestsMolecular Diagnostic TechniquesMutationBacterial ProteinsDNA, BacterialDNA-Directed RNA PolymerasesRifampinrpoB protein, Mycobacterium tuberculosisMycobacterium tuberculosistargeted next-generation sequencingtuberculosisXpert MTB/RIF

Identifiers

PMID38602399
PMCPMC11064545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.